Astellas Pharma shares positive results from phase 3b trial of Fezolinetant for menopause symptoms
June 28, 2023Medical Communications Astellas Pharma, Pharmacy, clinical trial, fezolinetant, menopause
Astellas Pharma has announced positive topline results from the phase 3b DAYLIGHT clinical trial for fezolinetant, its investigational oral, nonhormonal …
Bristol Myers Squibb’s Sotyktu recommended for NHS use for adult patients with psoriasis
June 28, 2023Medical Communications Dermatology, NHS, Sotyktu, bristol myers squibb, psoriasis
Bristol Myers Squibb (BMS) has announced that the National Institute for Health and Care Excellence (NICE) has recommended Sotyktu (deucravacitinib) …
UK nonprofit National Cancer Research Institute to close
June 27, 2023Medical Communications Cancer, NCRI, National Cancer Research Institute, Oncology, oncology
The National Cancer Research Institute (NCRI) has announced that it is closing after 22 years of advancing cancer research. Established …
GSK receives FDA Fast Track designation for novel gonorrhoea vaccine
June 27, 2023Research and Development FDA, GSK, Infections and infestations, Vaccine, fast track designation, gonorrhoea
GSK has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for its investigational vaccine …
AstraZeneca’s Xigduo XR approved in China for adults with type-2 diabetes
June 27, 2023Medical Communications AstraZeneca, China, Diabetes, Xigduo XR, diabetes
AstraZeneca has announced that its Xigduo XR (dapagliflozin and metformin hydrochloride extended-release), a once-daily fixed-dose combination, has now been approved …
Verona Pharma submits FDA New Drug Application for COPD treatment
June 27, 2023Research and Development COPD, Cardiology, FDA, ensifentrine, new drug application, verona pharma
UK-based Verona Pharma has announced that it has submitted a New Drug Application (NDA) to the US Food and Drug …
Sanofi shares data about new drug for haemophilia A in paediatric patients
June 26, 2023Research and Development Haematology, Sanofi, clinical trial, haemophilia a
Sanofi has shared new data from the phase 3 XTEND-Kids study which assessed Altuviiio (Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein) …
FDA approves Pfizer’s Litfulo for patients with severe alopecia areata
June 26, 2023Medical Communications FDA, Litfulo, Pfizer, Pharmacy, alopecia, alopecia areata
Pfizer has announced that the US Food and Drug Administration (FDA) has approved its Litfulo (ritlecitinib) for patients over the …
AstraZeneca’s Soliris given EU CHMP recommendation for marketing authorisation
June 26, 2023Medical Communications AstraZeneca, CHMP, EMA, Immunology, soliris
UK-based biopharmaceutical company AstraZeneca has announced that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) …
CHMP gives positive opinion recommending authorisation to GSK’s CKD drug
June 26, 2023Medical Communications CKD, EMA, Nephrology
Global biopharmaceutical company GSK has announced that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) …
Cartesian Therapeutics announces successful trial of RNA cell therapy in autoimmunity
June 23, 2023Research and Development Cartesian Therapeutics, Neurology, RNA, autoimmune, neurology
Clinical stage biotechnology company, Cartesian Therapeutics, has announced results from its clinical trial using RNA CAR T (rCAR T) therapy …
Moderna files for FDA authorisation for updated COVID-19 vaccine
June 23, 2023Research and Development COVID-19, FDA, Immunology, Moderna, Vaccine
Biotechnology company Moderna has announced that it has completed submission of a regulatory application to the US Food and Drug …
XOMA acquires royalty and milestone rights for NPC and pancreatic cancer assets
June 23, 2023Sales and Marketing Cancer, Oncology, Xoma, acquisition, oncology
US-based biotechnology royalty aggregator XOMA has announced that it has gained the royalty and milestone rights for two assets from …
GSK settles first Zantac lawsuit due for trial in US
June 23, 2023Medical Communications Cancer, GSK, Pharmacy, Zantac, lawsuit
UK-based pharmaceutical and biotechnology company GSK has reached a settlement with a US man who claims the drugmaker’s heartburn medicine …
Lupin Healthcare launches Beclu carbon neutral inhalers for asthma treatment
June 22, 2023Research and Development Asthma & COPD, Beclu, Lupin Healthcare, asthma, carbon neutral, inhaler
UK-based subsidiary of Lupin Limited, Lupin Healthcare, has announced the UK launch of its carbon neutral pressurised metered dose inhalers …
FDA approves new medicines to treat paediatric type 2 diabetes
June 22, 2023Medical Communications Diabetes, FDA, Synjardy, jardiance, paediatrics, type 2 diabetes
The US Food and Drug Administration (FDA) has announced that it has approved Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin …
Hyloris enrols first patient in four-arm clinical trial
June 22, 2023Research and Development Genito-Urinary system, Hyloris, bladder pain, clinical trial, cystitis
Belgian specialty biopharmaceutical company Hyloris has announced that it has enrolled the first patient in its four-arm interstitial cystitis/bladder pain …
Zymeworks to open new EU HQ in Dublin, Ireland
June 22, 2023Business Services Dublin, Oncology, Zymeworks, headquarters, regulatory affiars
Canadian biotech company Zymeworks has announced plans to open its new Clinical and Regulatory EU headquarters in Dublin, Ireland. Zymework …
Eli Lilly to acquire DICE Therapeutics for immunology innovations
June 21, 2023Business Services DICE Therapeutics, Eli Lilly, Immunology, acquisition, immunology
Eli Lilly and DICE Therapeutics have announced a definitive agreement for Lilly to acquire DICE, a biopharmaceutical company focusing on …
GSK shares positive data for RSV vaccine
June 21, 2023Research and Development GSK, Immunology, RSV, Vaccine, clinical trial
GSK have announced new positive data from the AReSVi-006 phase 3 trial which assessed the efficacy of a single dose …
Latest content
FibroFind appoints Lee Borthwick as CEO
